phrykt

Zevra Therapeutics, Inc. (ZVRA): who owns it and who trades it

As of Nov 16, 2026, ZVRA insiders reported 13 open-market sales worth $2.5M and no purchases in the last 12 months, with 95% of the sale value made under pre-set 10b5-1 plans. The largest seller was Neil F. McFarlane (CEO), with $1.2M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Zevra Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ZVRA

157 funds and institutions reported ZVRA shares worth $670M at the end of Q2 2026, about 80% of the company. The largest holder is BlackRock, Inc. with 8.7%.

Funds and institutions (13F) 80%Everyone else 20%

10 largest owners, by share of the company

BlackRock, Inc.8.7%
FMR LLC (Fidelity)8.4%
Woodline Partners LP8.2%
Nantahala Capital Management, LLC6.1%
Vanguard Capital Management LLC4.5%
State Street Corp2.9%
Geode Capital Management, LLC2.6%
D. E. Shaw & Co., Inc.2.2%
Qube Research & Technologies Ltd2.1%
Morgan Stanley2.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.5.11M8.70%$73.3M+15%
FMR LLC (Fidelity)4.92M8.37%$70.5M+53%
Woodline Partners LP4.79M8.15%$68.6M+39%
Nantahala Capital Management, LLC3.59M6.12%$51.6M+43%
Vanguard Capital Management LLC2.64M4.49%$37.8M+7%
State Street Corp1.68M2.86%$24.1M+8%
Geode Capital Management, LLC1.54M2.62%$22.1M+12%
D. E. Shaw & Co., Inc.1.31M2.23%$18.7M+54%
Qube Research & Technologies Ltd1.24M2.11%$17.8M+47%
Morgan Stanley1.20M2.05%$17.3M+1%
Legal & General Group Plc1.20M2.05%$17.2M+3%
Dimensional Fund Advisors LP958,8361.63%$13.7M+73%
Royce & Associates LP882,6581.50%$12.7M-11%
683 Capital Management, LLC855,0001.46%$12.3M-12%
Kingdon Capital Management, L.l.c.775,0001.32%$11.1MNo change
Retirement Planning Co of New England, Inc.634,4101.08%$9.1M-3%
Jupiter Topco LLC613,4031.04%$8.8M–
Arrowstreet Capital, Limited Partnership597,1621.02%$8.6M–
Goldman Sachs Group Inc545,5510.93%$7.8M-27%
Vanguard Portfolio Management LLC541,1090.92%$7.8M+16%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ZVRA insiders reported $0 of open-market purchases and $2.5M of sales. 95% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$2.5M
13 trades, 6 people
Sales under a 10b5-1 plan
95%
Share of sale value
Latest trade
Oct 12, 2026
Filed Oct 13, 2026

Purchases and sales by month

$1.1M$1.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 12, 2026Neil F. McFarlaneCEOSale plan20,000$11.25$225KForm 4
Aug 14, 2026Rahsaan ThompsonChief Legal & ComplianceSale plan42,666$11.13$475KForm 4
Aug 10, 2026Corey Michael WattonDirectorSale12,300$11.25$138KForm 4
Jun 22, 2026Rahsaan ThompsonChief Legal & ComplianceSale plan34,557$12.68$438KForm 4
May 11, 2026Rahsaan ThompsonChief Legal & ComplianceSale plan1,794$11.30$20.3KForm 4
Feb 9, 2026Neil F. McFarlaneCEOSale plan14,625$8.56$125KForm 4
Feb 3, 2026Timothy J. SangiovanniVice presidentSale plan3,000$9.18$27.5KForm 4
Feb 3, 2026Joshua SchaferCCOSale plan10,500$9.19$96.5KForm 4
Feb 2, 2026Neil F. McFarlaneCEOSale plan91,000$9.38$854KForm 4
Jan 30, 2026Timothy J. SangiovanniVice presidentSale plan1,750$8.82$15.4KForm 4
Jan 30, 2026Rahsaan ThompsonChief Legal & ComplianceSale plan4,080$8.83$36KForm 4
Jan 30, 2026Adrian W QuartelChief Medical OfficerSale plan4,533$8.83$40KForm 4
Jan 30, 2026Joshua SchaferCCOSale plan3,375$8.83$29.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Neil F. McFarlanePresident and CEO, Director–$1.2MOct 12, 2026
Rahsaan ThompsonChief Legal & Compliance–$969KAug 14, 2026
Corey Michael WattonDirector–$138KAug 10, 2026
Joshua SchaferCCO–$126KFeb 3, 2026
Timothy J. SangiovanniSVP, Finance & Corp Controller–$43KFeb 3, 2026
Adrian W QuartelChief Medical Officer–$40KJan 30, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ZVRA short interest

High short interest. 11.0% of ZVRA shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went up 48%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 6.56M ZVRA shares were sold short, 11.0% of the shares outstanding, up 5.3% from the report before. At the average daily volume of 690,195 shares, buying them all back would take about 9.5 trading days (days to cover).

Shares short, % of all shares

11.0%May 15Oct 3014.1%

Days to cover

9.5May 15Oct 3010.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.56M11.02%+5%690,1959.5
Oct 15, 20266.23M10.48%-13%879,2037.1
Sep 30, 20267.15M12.04%+25%998,1617.2
Sep 15, 20265.74M9.66%-1%905,9806.3
Aug 31, 20265.77M9.72%-11%773,3197.5
Aug 14, 20266.47M10.90%-9%1.12M5.8
Jul 31, 20267.13M12.01%-9%1.62M4.4
Jul 15, 20267.80M13.28%+20%1.43M5.4
Jun 30, 20266.49M11.05%-0%1.50M4.3
Jun 15, 20266.52M11.11%+9%2.33M2.8
May 29, 20265.96M10.16%+34%2.18M2.7
May 15, 20264.44M7.57%-11%1.76M2.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Zevra Therapeutics company events

Zevra Therapeutics filed 9 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 3, 2026.

  1. Nov 3, 2026ResultsReleased financial results. Filing
  2. Aug 5, 2026ResultsReleased financial results. Filing
  3. Jun 5, 2026VoteReported shareholder vote results. Filing
  4. May 6, 2026ResultsReleased financial results. Filing
  5. Mar 16, 2026AgreementZevra Therapeutics, Inc. entered into an Asset Purchase and Settlement Agreement with Commave Therapeutics SA to sell certain assets of the Company to Commave and to resolve litigation pending in the Court of Chancery of the State of Delaware captioned Commave Therapeutics SA v. Filing
  6. Mar 9, 2026LeadershipThe Company appointed Justin Renz as Chief Financial Officer and Treasurer, effective March 9, 2026, and as principal financial officer, effective March 10, 2026. Filing
  7. Dec 17, 2025LeadershipThe board of directors of Zevra Therapeutics, Inc. appointed Timothy Sangiovanni, the Company’s current Senior Vice President, Finance and Corporate Controller and principal accounting officer, as interim principal financial officer, effective as of January 1, 2026. Filing
  8. Dec 2, 2025LeadershipWendy Dixon notified the board of directors of Zevra Therapeutics, Inc. that she was resigning from the Board and each committee of the Board on which she served, subject to the Board’s acceptance. Filing
  9. Nov 20, 2025LeadershipR. LaDuane Clifton, the Chief Financial Officer and Treasurer and principal financial officer of Zevra Therapeutics, Inc. notified the Company of his decision to resign from his position, effective December 31, 2025, in order to pursue other professional opportunities. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Zevra Therapeutics financials

Famous investors that hold ZVRA

2 of the 50 well-known investors we track reported holding ZVRA in their latest 13F filing. The largest position is Ken Griffin's, worth $4.9M.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026448,934$4.9M0.0%+3590%
Israel Englander · Millennium ManagementQ3 2026408,339$4.5M0.0%+351%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ZVRA in the last 120 days.

FiledHolderFormStake
Nov 5, 2026FMR LLC13G/A9.4%
Nov 5, 2026FMR LLC13G/A9.4%

Questions about Zevra Therapeutics, Inc. (ZVRA) stock

Who owns the most ZVRA stock?

The largest reported owner of Zevra Therapeutics, Inc. (ZVRA) is BlackRock, Inc., with 8.7% of the company. In total, 157 funds and institutions reported holding ZVRA at the end of Q2 2026, together about 80% of the shares. See the largest owners.

Are ZVRA insiders buying or selling?

In the last 12 months, ZVRA insiders reported no open-market purchases and 13 sales worth $2.5M. The latest trade was on Oct 12, 2026. See every trade.

What is the short interest in ZVRA?

As of Oct 30, 2026, 6.56M ZVRA shares were sold short, 11.0% of the shares outstanding, up 5.3% from the report before. At the average daily volume of 690,195 shares, buying them all back would take about 9.5 trading days (days to cover). See the history.

Which famous investors hold ZVRA?

2 of the 50 well-known investors we track reported ZVRA in their latest 13F filing, including Ken Griffin, Israel Englander. The largest position is worth $4.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.